Hemostasis and bleeding disorders Interactive e-learning

Von Willebrand Disease Emergency Care: An Interactive Patient Case Study

How will your clinical decisions impact these patients?

Assoc. Prof. Jan Blatný

Dr Michael A Mazzeffi

Publication Date

Mar 2023

* To replay the media content and watch again, please refresh your screen

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

In this interactive patient case study developed by international experts, you'll follow two different von Willebrand disease (VWD) patient cases, make educated decisions about their care, and see how your answers impact the patients' trajectories.

After taking part, you'll understand the occurrence and impact of VWD in the emergency care setting, how to treat and manage VWD in daily clinical practice, and how to implement international VWD guidelines.

Take the interactive cases or follow the link to take the accredited e-learning to count towards your CME credit.

Looking to take the interactive patient case study on your phone? Coming soon – the smartphone version.

In the meantime, enjoy the course on desktop and tablet.

Clinical Takeaways

Refer to the haematologist for diagnostic testing if you suspect a bleeding disorder in your patient, as coagulation screening tests may be normal in some cases
Consult a haematologist before performing any invasive procedures, planned or acute, and in case of trauma in a patient with von Willebrand disease
Patients with VWD may need a haemostatic treatment plan in place before you proceed

Jan Blatný, MD, PhD, is Consultant Haematologist at the Department of Paediatric Haematology and Biochemistry, Centre for Thrombosis and Haemostasis and the Director of the Haemophilia Comprehensive Care Centre of University Hospital in Brno, Czech Republic. He is also an Associate Professor of Paediatrics at Masaryk University in Brno, Czech Republic. His research interests encompass paediatric haematology, thrombosis and haemostasis, and life-threatening bleeding. He is a member of the Working Party on population PK of the ISTH SSC Subcommittee on Factor VIII and IX and Rare Bleeding Disorders. In addition to ISTH, Dr Blatný is a member of numerous national and international haematology organizations. He serves on the steering committee and is a paediatric coordinator of the Czech National Haemophilia Programme, Vice-president and a member of Executive Committee of EAHAD, member of MAG (Medical advisory group) of EHC, a reviewer for several haematology journals, and is on the editorial board for an official journal of Czech Haematology society. Dr Blatný’s publication credits are 9 book chapters and over 100 articles published in peer-reviewed journals

Assoc. Prof. Jan Blatný has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Novo Nordisk, Pfizer, Roche, Sobi and Takeda.

Dr Mazzeffi is a cardiothoracic anesthesiologist and intensive care physician. He is currently Vice Chair for Faculty Affairs and Development in the department of anesthesiology at University of Virginia Health. He is an active clinical researcher with an interest in hemostasis, viscoelastic coagulation testing, extracorporeal membrane oxygenation, and acquired Von Willebrand Syndrome in patients on mechanical circulatory support. He is an active teacher and mentor for medical students, anesthesiology residents and fellows.

Dr Michael A Mazzeffi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Hemosonics Corporation and Octapharma.